Biorestorative Therapies, INC. (BRTX) — 10-K Filings
All 10-K filings from Biorestorative Therapies, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
BioRestorative Therapies Accelerates BRTX-100, Eyes Phase 3 Amid Funding Gap
— Mar 26, 2026 Risk: high
BioRestorative Therapies, Inc. (BRTX) is focused on developing adult stem cell therapies for disc/spine conditions and metabolic disorders, alongside a commerci -
BioRestorative Therapies Files 2024 10-K
— Mar 28, 2025 Risk: medium
BioRestorative Therapies, Inc. filed its 10-K for the fiscal year ending December 31, 2024. The company, formerly known as Stem Cell Assurance, Inc., is involve -
BioRestorative Therapies, Inc. Files 2023 Annual Report on Form 10-K
— Apr 1, 2024 Risk: medium
BioRestorative Therapies, Inc. (BRTX) filed a Annual Report (10-K) with the SEC on April 1, 2024. BioRestorative Therapies, Inc. filed its annual report for the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX